 Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: The efficacy of nivolumab combined with low-dose ipilimumab in the first-line treatment of MSI-H/dMMR metastatic colorectal cancer

J Clin Oncol: The efficacy of nivolumab combined with low-dose ipilimumab in the first-line treatment of MSI-H/dMMR metastatic colorectal cancer

 Last Update: 2021-10-20
 Source: Internet
 Author: User

Tags

vortex 1 10

vitamin b17 cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Based on the CheckMate 142 study, Nivolumab was approved by the US FDA as a single agent or combined with Ipilimumab for the treatment of high microsatellite instability/mismatch repair defects (MSI-H/dMMR) Of metastatic colorectal cancer (mCRC) that has progressed after treatment with fluoropyrimidine, oxaliplatin, and irinotecan
.

FDA colorectal cancer

This article reports the results of nivolumab combined with low-dose ipilimumab as a first-line treatment for MSI-H/dMMR CRC patients in the Phase II CheckMate 142 study
.

Patients with previously untreated metastatic MSI-H/dMMR CRC received nivolumab (1 time/2 weeks) combined with low-dose ipilimumab (1 time/6 weeks) until the disease progressed
.

The primary endpoint is the objective response rate

Progression-free survival

A total of 45 patients were recruited, with a median age of 66 years
.

The median follow-up was 29.

The objective response rate and disease control rate were 69% (95% CI 53-82) and 84% (95% CI 70.

Overall survival rate

At the shortest follow-up of 24.
2 months, neither the median progression-free survival nor the median overall survival was reached; the progression-free survival rate and overall survival rate at 24 months were 74% and 79%, respectively
.

Regardless of baseline demographics and tumor characteristics (including BRAF and KRAS mutation status), clinical benefit was observed

The progression-free survival rate and overall survival rate at 24 months were 74% and 79%, respectively.

The occurrence of adverse events

22% of patients experienced grade 3-4 treatment-related adverse events; 13% of patients discontinued treatment due to treatment-related adverse events
.

In summary, nivolumab combined with low-dose ipilimumab as a first-line treatment has shown strong and lasting clinical benefits and good tolerability in patients with MSI-H/dMMR mCRC
.

Based on these data, relevant randomized trials can be further carried out

Wu satisfied monoclonal antibody combined with low doses of ipilimumab as first-line therapy demonstrated a powerful and long-lasting clinical benefit and well tolerated in MSI-H / dMMR mCRC patients satisfied Wu monoclonal antibody combined with low doses of ipilimumab as The first-line treatment has demonstrated strong and long-lasting clinical benefits and good tolerability in patients with MSI-H/dMMR mCRC

Original source:

Heinz-Josef Lenz, et al.

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High / Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.